Global Post-Traumatic Stress Disorder (PTSD) Market Growth (Status and Outlook) 2025-2031

According to this study, the global Post-Traumatic Stress Disorder (PTSD) market size will reach US$ million by 2031.

Post-traumatic stress disorder (PTSD) is a delayed and persistent mental disorder that occurs when an individual experiences, witnesses, or encounters one or more actual deaths involving himself or others, or is threatened with death, or is severely injured, or whose physical integrity is threatened.The incidence of PTSD has been reported inconsistently, with women more likely to develop PTSD than men.

United States market for Post-Traumatic Stress Disorder (PTSD) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Post-Traumatic Stress Disorder (PTSD) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Post-Traumatic Stress Disorder (PTSD) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Post-Traumatic Stress Disorder (PTSD) players cover GlaxoSmithKline (UK), Pfizer (US), Eli Lilly and Company (US), Lundbeck A/S (Denmark), Azevan Pharmaceuticals (US), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Post-Traumatic Stress Disorder (PTSD) Industry Forecast” looks at past sales and reviews total world Post-Traumatic Stress Disorder (PTSD) sales in 2024, providing a comprehensive analysis by region and market sector of projected Post-Traumatic Stress Disorder (PTSD) sales for 2025 through 2031. With Post-Traumatic Stress Disorder (PTSD) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Post-Traumatic Stress Disorder (PTSD) industry.

This Insight Report provides a comprehensive analysis of the global Post-Traumatic Stress Disorder (PTSD) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Post-Traumatic Stress Disorder (PTSD) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Post-Traumatic Stress Disorder (PTSD) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Post-Traumatic Stress Disorder (PTSD) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Post-Traumatic Stress Disorder (PTSD).

This report presents a comprehensive overview, market shares, and growth opportunities of Post-Traumatic Stress Disorder (PTSD) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Cognitive Therapy
Exposure Therapy
Eye Movement Desensitization And Reprocessing (EMDR)
Antidepressants
Anti-Anxiety Medications
Prazosin

Segmentation by Application:
Children
Adult

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GlaxoSmithKline (UK)
Pfizer (US)
Eli Lilly and Company (US)
Lundbeck A/S (Denmark)
Azevan Pharmaceuticals (US)
Marinus Pharmaceuticals, Inc. (US)
Tonix Pharmaceuticals Holding Corp. (US)
Bionomics (Australia)
Greenstone LLC (US)
Mylan NV (US)
Otsuka Pharmaceutical (Japan)
Prometheon Pharma (USA)
Ligand Pharma (USA)
Valenta Pharm (Russia)
Lycera Corp (US)
Archimedes (UK)
GMP Endotherapeutics (USA)
Nuvo Pharmaceuticals (Canada)
Beijing Wansheng Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhejiang Jianfeng Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver. Show more